Blackbaud (BLKB)
(Delayed Data from NSDQ)
$83.60 USD
+0.15 (0.18%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $83.59 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.60 USD
+0.15 (0.18%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $83.59 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Blackbaud (BLKB) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Blackbaud's (BLKB) second-quarter 2022 revenues benefit from increased recurring revenues and higher transactional volume, partly offset by changing macroeconomic
Blackbaud (BLKB) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Blackbaud (BLKB) delivered earnings and revenue surprises of 8.70% and 0.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Blackbaud (BLKB) Warrants a Bullish Stance Now
by Zacks Equity Research
Blackbaud (BLKB) is well-poised to gain from accelerated cloud migration by enterprises taking place globally
Blackbaud (BLKB) Adds Prospect Insights to Raiser's Edge NXT
by Zacks Equity Research
Blackbaud (BLKB) announces the launch of Prospect Insights to offer multi-dimensional fundraising insights and actions.
Why Is Blackbaud (BLKB) Up 12.5% Since Last Earnings Report?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Blackbaud (BLKB) Climb 37% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 37.1% upside potential for Blackbaud (BLKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Blackbaud (BLKB) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Blackbaud's (BLKB) first-quarter 2022 revenues benefit from increased recurring revenues and higher transactional volume.
Blackbaud (BLKB) Q1 Earnings Miss Estimates
by Zacks Equity Research
Blackbaud (BLKB) delivered earnings and revenue surprises of -12.31% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Manhattan Associates (MANH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Manhattan Associates (MANH) delivered earnings and revenue surprises of 33.33% and 6.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Blackbaud (BLKB) Adopts Sustainability Reporting, Boosts ESG Goals
by Zacks Equity Research
Blackbaud (BLKB) became carbon-free for 2021 by using energy efficiently and investing in eco-friendly projects in its quest to build a green future.
Zacks.com featured highlights Ligand Pharmaceuticals, Las Vegas Sands, CoStar Group and Blackbaud
by Zacks Equity Research
Ligand Pharmaceuticals, Las Vegas Sands, CoStar Group and Blackbaud have been highlighted in this Screen of the Week article.
Don't Let These Toxic Stocks Disrupt Your Portfolio
by Rimmi Singhi
Ligand (LGND), Las Vegas Sands (LVS), CoStar (CSGP) and Blackbaud (BLKB) are a few toxic stocks that you should dump to avoid portfolio bleeding.
Blackbaud (BLKB) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blackbaud (BLKB) Now Boasts PayPal and Venmo Payment Options
by Zacks Equity Research
Blackbaud (BLKB) noted that the integrations with PayPal and Venmo will enable social good organizations to create a safe and seamless checkout experience for registration, donations and so on.
Blackbaud (BLKB) Collaborates With Change Donation Platform
by Zacks Equity Research
Blackbaud (BLKB) partners with the Change donation platform to provide companies with "customer-facing giving experiences."
Blackbaud (BLKB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blackbaud's (BLKB) fourth-quarter 2021 revenues benefit from increases in recurring revenues.
Blackbaud (BLKB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blackbaud (BLKB) delivered earnings and revenue surprises of 11.94% and 2.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Blackbaud (BLKB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Blackbaud (BLKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include Caesars Entertainment, Blackbaud, Chegg and Sendas Distribuidora
by Zacks Equity Research
Caesars Entertainment, Blackbaud, Chegg and Sendas Distribuidora are included in this blog.
Protect Your Portfolio Health From These 4 Toxic Stocks
by Rimmi Singhi
Usually, toxic stocks are fraught with huge debt loads and are susceptible to external shocks. CZR, BLKB, CHGG and ASAI are some stocks that you should sell now to detoxify your portfolio.
Save Your Portfolio by Getting Rid of These 4 Toxic Stocks
by Rimmi Singhi
Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.
Blackbaud (BLKB) Buys EVERFI for $750M: Major Takeaways
by Zacks Equity Research
Blackbaud's (BLKB) EVERFI acquisition expands the company's total addressable market to more than $20 billion
Why Is Blackbaud (BLKB) Down 12.3% Since Last Earnings Report?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Blackbaud (BLKB) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Blackbaud (BLKB) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blackbaud's (BLKB) third-quarter 2021 revenues benefit from increases in recurring revenues.